​​Allergy in 2025: Year in Review

The past year saw significant progress in allergy and immunology, with multiple US Food & Drug Administration (FDA) approvals expanding treatment options for hereditary angioedema (HAE), including donidalorsen, sebetralstat, and garadacimab-gxii. Clinicians now have access to therapies that improve attack prevention, offer oral and less frequent dosing options, and provide new tools for pediatric patients, addressing long-standing gaps in care.